Seasoned Financial Executive Jeff Bruner Joins Aventiv Research
COLUMBUS, OH, March 16, 2020 /24-7PressRelease/ — Aventiv Research, a leading independent, multi-therapeutic inpatient and outpatient clinical research center, is pleased to announce the appointment of Jeff Bruner as Chief Financial Officer (CFO). As CFO, Bruner acts as a strategic financial partner for Aventiv where he provides financial analysis and recommendations that optimize value for the company. Bruner brings with him 30 years of experience assisting clients with financial planning, risk management, record-keeping, and reporting.
In addition to his role with Aventiv, Bruner is a shareholder with Brixey & Meyer where he engages with many clients as fractional CFO. He holds a degree in finance from Purdue University and is a Certified Management Accountant (CMA).
As a member of the leadership team, Bruner reports directly to President and Medical Director, Dr. Samir Arora. “Jeff was able to quickly assess the financial position of our organization and has already assisted us with making necessary strategic decisions to optimize performance,” commented Arora. “His ability to leverage his experience, along with his passion and energy, fit well with the culture we’ve built at Aventiv.”
Bruner is excited about the foundation Aventiv has built to support its future growth. “Leadership has a tremendous operating system in place that’s embraced by the staff,” stated Bruner. “They’ve identified critical success factors and acquired technical expertise to ensure rapid growth. This is the type of environment that I find exciting and where the most value can be realized.”
For more information about Jeff Bruner and Aventiv Research, visit www.aventivresearch.com.
About Aventiv Research
Aventiv Research exists to make novel medicines accessible to its patients and deliver industry-best pharmaceutical data to its sponsors. Its mission is to enrich the lives of both its team members and patients by putting medical research to work. Currently operating in three states with five independent research sites, Aventiv specializes in phase I-IV pharmaceutical, device, and diagnostic clinical trials in a variety of therapeutic areas. Built on the core values of dedication, integrity, resourcefulness, and professionalism, the company embraces a visionary, entrepreneurial spirit that compels its ambassadors to blaze new trails with proprietary systems and processes.
Founded in 2007 by Dr. Samir Arora, a proven leader with more than 15 years of clinical research experience, Aventiv Research has conducted over 450 clinical trials with more than 55 pharmaceutical sponsors and has helped 14 drugs to become approved by the FDA and available for use.
For the original version of this press release, please visit 24-7PressRelease.com here